Kenvue, Inc. (KVUE) AI Stock Analysis

Kenvue, Inc.

(BMV:KVUE)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Sustained sales growth and executionFour consecutive quarters of net and organic sales growth indicate improving execution and product demand across the portfolio. Combined with margin expansion and strong cash generation, this supports a more durable recovery in operating performance over the next several quarters.

Negative Factors

Meaningful leverage limits flexibilityAlthough the capital structure is described as manageable, debt remains meaningful relative to equity and can constrain financial flexibility if operating conditions weaken. Leverage may also limit the capacity to fund growth initiatives or absorb weaker cash generation without adjusting capital allocation.

Kenvue, Inc. (KVUE) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 37.09B
Dividend Yield: 4.71%
Average Volume (3M): 150
Price to Earnings (P/E): 21.9
Beta (1Y): -0.05
Revenue Growth: -7.22%
EPS Growth: 5.75%
Country: Mexico
Employees: 21,890
Sector: Consumer Defensive
Sector Strength: 62
Industry: Household & Personal Products

Kenvue, Inc. Business Overview & Revenue Model

Company Description

Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse rang...

Kenvue, Inc. Earnings Call Summary

Earnings Call Date:Jul 13, 2025(Q2-2025)|% Change Since:3.26%|Next Earnings Date:Feb 10, 2027

Earnings Call SentimentNeutral

The earnings call highlighted Kenvue's strengths in market share gains and leadership improvements but was overshadowed by underwhelming financial performance and challenges in key markets. The revised guidance and focus on strategic alternatives suggest a period of transition and uncertainty.

Positive Updates

Strong Market Share in Self Care

In the U.S., 83% of Kenvue's Self Care business held or gained market share, with ZYRTEC growing household penetration and Tylenol achieving its 12th consecutive quarter of share improvement.

Negative Updates

Disappointing Q2 Financial Performance

Organic sales declined 4.2% year-over-year, which was below expectations. Adjusted operating margin contracted 10 basis points to 22.7%, and adjusted diluted EPS fell to $0.29 from $0.32.

Company Guidance

During Kenvue's Second Quarter 2025 Earnings Conference Call, the company revised its guidance for fiscal 2025, projecting organic sales to decline in the low single digits with a roughly neutral impact from currency fluctuations. The adjusted operating margin is expected to contract due to strategic price investments, fixed cost deleverage, and inflationary pressures, which productivity initiatives may not fully offset. Consequently, adjusted diluted EPS is anticipated to range between $1 to $1.05, considering a low single-digit drag from currency. The company highlighted a challenging second quarter, with organic sales declining by 4.2% and adjusted operating margin decreasing by 10 basis points to 22.7%, leading to an adjusted diluted EPS of $0.29. Despite these results, Kenvue remains committed to enhancing operational rigor, improving execution, and strategically reviewing alternatives to unlock shareholder value.

Kenvue, Inc. Risk Analysis

Kenvue, Inc. disclosed 144 risk factors in its most recent earnings report. Kenvue, Inc. reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Kenvue, Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (62)

Financial Indicators

MX:KVUE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PG	72Outperform	$374.48B	24.23	29.55%	2.64%	3.52%	-3.74%
KMB	70Outperform	$35.90B	18.41	122.57%	4.71%	-12.19%	-19.22%
CL	67Neutral	$75.96B	37.85	1135.82%	2.17%	5.91%	-28.30%
UL	64Neutral	$140.61B	13.82	58.26%	3.35%	-17.45%	8.84%
Sector *	62Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
EL	58Neutral	$39.58B	102.72	9.28%	1.34%	6.18%	―

* Consumer Defensive Sector Average

Performance Comparison

MX:KVUE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:KVUE	Kenvue, Inc.	376.00	89.95	31.45%
CL	Colgate-palmolive Company	97.43	22.32	29.72%
EL	Estée Lauder	104.77	14.96	16.65%
KMB	Kimberly Clark	108.25	13.07	13.74%
PG	Procter & Gamble Company	163.56	21.88	15.44%
UL	Unilever plc	66.44	2.97	4.68%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Kenvue, Inc. AI Stock Analysis